Who
Joakim Wijkstrom
SVP, Chief Marketing Officer
Company insider
Files Form 4 as: SVP, Chief Marketing Officer, Vanda Pharmaceuticals.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $961K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 19 Aug 2019
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $255K30,800 at $8.27 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $255K30,800 at $8.27 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $74K15,520 at $4.76 | filing |
| 18 Feb 2025filed 20 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 5 Mar 2024filed 6 Mar 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $39K9,229 at $4.21 | filing |
| 4 Mar 2024filed 6 Mar 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $33K7,498 at $4.41 | filing |
| 16 Feb 2024filed 21 Feb 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —32,700 at $0.00 | filing |
| 21 Aug 2023filed 23 Aug 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $22K3,724 at $5.84 | filing |
| 3 Mar 2023filed 6 Mar 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $26K4,113 at $6.32 | filing |
| 2 Mar 2023filed 6 Mar 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $48K7,720 at $6.23 | filing |
| 16 Feb 2023filed 21 Feb 2023 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 16 Feb 2023filed 21 Feb 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —32,700 at $0.00 | filing |
| 22 Aug 2022filed 23 Aug 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $37K3,605 at $10.27 | filing |
| 2 Mar 2022filed 2 Mar 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $78K6,974 at $11.19 | filing |
| 28 Feb 2022filed 2 Mar 2022 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 28 Feb 2022filed 2 Mar 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —32,700 at $0.00 | filing |
| 20 Aug 2021filed 23 Aug 2021 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $56K3,650 at $15.39 | filing |
| 2 Mar 2021filed 3 Mar 2021 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $72K3,888 at $18.45 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Joakim Wijkstrom; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.